Animal-free innovations in safety assessment of chemicals How can the process of validation, acceptance and use of animal-free innovative approaches to assess the safety of chemicals be facilitated?
First products Dutch Public Health Foresight study available in English In 2017, RIVM launched a Trend Scenario, as well as three thematic reports about the future demand for health care, technology and wider determinants of health.
New test has no added value in Lyme disease of the central nervous system Active Lyme disease of the central nervous system cannot be detected with an ELISpot test.
New standard for exposure assessment of cleaning products RIVM has updated the standard for exposure assessment of cleaning products in the ConsExpo Cleaning Products Fact Sheet.
Influenza-like Illness Incidence Is Not Reduced by Influenza Vaccination Influenza vaccination reduces the number of influenza virus infections but not the overall number of illness.
Trend scenario PHF- 2018 identifies societal challenges for the future If historical trends continue unchanged, dementia will be the leading cause of disease burden in 2040 and the main cause of death.
Lyme disease costs EUR 20 million annually The societal costs of Lyme disease have been determined for the Netherlands for the first time. The disease appears to cost nearly EUR 20 million each year.
RIVM launches new web-based version of ConsExpo An improved version of the computer program ConsExpo is now available via the RIVM website.
Moderate flu season Last winter season, the duration and severity of the influenza epidemic was moderate compared to previous years.
Lab tests alone not conclusive for diagnosis of Lyme disease Lyme disease can cause a variety of complaints in patients. Laboratory tests for the disease can support medical practitioners in making a diagnosis but are not necessarily conclusive.